LDS/Medical Tests/Coagulation Factor X Inhibitor Screen, Plasma

Coagulation Factor X Inhibitor Screen, Plasma

Factor X is a member of the common coagulation pathway, in conjunction with Factor V and Calcium, that converts prothrombin into thrombin, which in turn converts fibrinogen to fibrin. Coagulation tests to assess the activity of the common pathway usually include the thrombin time test and a fibrinogen assay. Factor X disorders will usually prolong the Prothrombin Time, Activated Partial Thromboplastin time, and the Russell’s Viper Venom Time Test. It also correlates by being corrected upon mixing studies. Inherited Factor X deficiency is possible; however, it is extremely rare. The occurrence is 1 per 500,000. Notable deficiency can happen at any age and the severest of symptoms pertain to the very young. For most individuals a level of 10% (as compared to a normal individual with 100%) is adequate for hemostasis. Treatment for deficiency consists of fresh frozen plasma therapy or prothrombin-complex concentrates.

Clinical symptoms of deficiency range from easy bruising in mild cases to postoperative hemorrhage in very severe cases. Family history and clinical data are useful indicators in differentiating inherited verses acquired deficiency. Other factors to assess are liver disease and vitamin K deficiency. Factor X deficiency has been noted in amyloidosis and also due to variant forms of Factor X because of amino acid substitution or deletions.

  • Diagnosis of congenital or acquired coagulation factor X deficiency
  • To evaluate hemostatic function in liver disease
  • Assessment of a prolonged PT and aPTT

Decreased in:

  • Bruising
  • Epitaxis
  • Gastrointestinal Bleeding
  • Menorrhagia
  • Prolonged PT and aPTT
  • Poor Diet
  • Oral Anticoagulants

60 - 150 %
 

 

Clotting Assays using a mixture of patient plasma and factor X deficient plasma in a mixture in a prothrombin test method. Alternately, chromogenic assays use Russell's viper venom and patient plasma to activate patient factorX which in turn hydrolyzes a chromogenic substrate to release a chromophore that is measured optically by light absorption at a specific wavelenth of light.

Plasma Citrate (Blue Top)

Stability

  • Ambient: Unacceptable
  • Refrigerated: Unacceptable
  • Frozen: 60 days
  • Separate Plasma and freeze immediately. Maintain frozen until testing.
Mixing Studies, PT, aPTT, Russell’s Viper Venom time, Thrombin Time, Fibrinogen, Vitamin K level.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Kessler C. Hemorrhagic disorders: Coagulation factor deficiencies. In: Goldman L, Ausiello D (eds.) Cecil Medicine. 23rd ed. Philadelphia, Pa:Saunders Elsevier (2007). Ch. 180.
  • Harmening D. Clinical Hematology and Fundamentals of Hemostasis. Philadelphia: F. A. Davis Company (1997).
  • Gailani D and Neff AT. Rare coagulation factor deficiencies. In: Hoffman R, Benz EJ Jr., Shattil SJ, et al (eds.) Hoffman Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Churchill Livingstone Elsevier (2008). Ch. 127.